Ebola viruses are the causative agents of a severe form of viral haemorrhagic fever in man,
designated Ebola haemorrhagic fever, and are endemic in regions of central Africa. The …

Following the Ebola virus disease epidemic in west Africa, there has been increased
awareness of the need for improved therapies for emerging diseases, including viral …

Background rVSV-ZEBOV is a recombinant, replication competent vesicular stomatitis virus-
based candidate vaccine expressing a surface glycoprotein of Zaire Ebolavirus. We tested …

Without an approved vaccine or treatments, Ebola outbreak management has been limited
to palliative care and barrier methods to prevent transmission. These approaches, however …

Outbreaks of Ebola hemorrhagic fever in sub-Saharan Africa are associated with case
fatality rates of up to 90%. Currently, neither a vaccine nor an effective antiviral treatment is …

Background The worst Ebola virus disease (EVD) outbreak in history has resulted in more
than 28,000 cases and 11,000 deaths. We present the final results of two phase 1 trials of an …

Filovirus infections can cause a severe and often fatal disease in humans and nonhuman
primates, including great apes. Here, three anti-Ebola virus mouse/human chimeric mAbs …

The latest Ebola virus (EBOV) epidemic spread rapidly through Guinea, Sierra Leone, and
Liberia, creating a global public health crisis and accelerating the assessment of …

Summary Background The recent Sudan virus (SUDV) outbreak in Uganda highlights the
need for rapid response capabilities, including development of vaccines against emerging …

Since the discovery in 1796 by Edward Jenner of vaccinia virus as a way to prevent and
finally eradicate smallpox, the concept of using a virus to fight another virus has evolved into …